Lupin Collaborates with ERN For Luforbec Launch in Spain; Stock Trades Higher
By HDFC SKY | Published at: Jun 8, 2026 01:27 PM IST
Lupin partnered with Spain-based LABORATORIOS ERN to launch Luforbec pMDI for asthma and COPD treatment in the Spanish market.
Mumbai, March 8: Lupin announced a strategic collaboration with Spain-based LABORATORIOS ERN S.A. for the launch of Luforbec, a fixed-dose respiratory therapy for asthma and chronic obstructive pulmonary disease (COPD), in Spain.
According to the company’s exchange filing on Monday, the collaboration covers Luforbec (beclometasone/formoterol) 100/6, delivered through a pressurised metered dose inhaler (pMDI).
The company said the product is indicated for adult asthma and COPD treatment and combines Lupin’s respiratory manufacturing capabilities with ERN’s commercial presence in Spain.
Lupin added that the partnership strengthens its respiratory portfolio expansion strategy across Europe following launches in the UK and Germany.
Collaboration Expands European Respiratory Presence
Thierry Volle, President EMEA and Emerging Markets at Lupin, said the Spain launch marks another milestone in the company’s global respiratory expansion strategy.
The company stated that the collaboration combines Lupin’s expertise in pMDI manufacturing with ERN’s local market reach and customer relationships in Spain.
David Solanes, Chief Executive Officer of LABORATORIOS ERN, said the agreement provides an opportunity to expand into a new therapeutic segment while improving access to respiratory therapies in the Spanish market.
Luforbec is used for the regular treatment of asthma and symptomatic treatment of severe COPD in patients requiring long-acting bronchodilator therapy.
Stock Market Snapshot
Lupin share price traded marginally higher following the announcement.
The stock traded at ₹2,272.30 on the NSE, up 0.20% or ₹4.60 as of 12:36 PM IST on June 8, 2026, according to market data.
The gains reflected positive investor sentiment around the company’s continuing respiratory portfolio expansion and international commercial partnerships.
Source:
- https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited
- https://nsearchives.nseindia.com/corporate/Lupin2_08062026120647_SELetterPressRelease.pdf
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
Join Us
Add as preferred source on Google
